Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

Abstract Bevacizumab (BEV) combined with standard chemotherapy with carboplatin and paclitaxel (CP) as the front-line treatment for newly diagnosed advanced-stage epithelial ovarian cancer (EOC) is a promising treatment option. In Thailand, combined BEV and CP for patients with high-risk EOC is not...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Authors: Kanyarat Katanyoo, Usa Chaikledkaew, Nutthaporn Chandeying
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Subjects:
Ovarian cancer
Bevacizumab
Cost-effectiveness
Quality adjusted life year
Thailand
Online Access:https://doi.org/10.1038/s41598-025-94455-7

Internet

https://doi.org/10.1038/s41598-025-94455-7

Similar Items